8.1 Non-Sterile Compounding (USP <795>): Categories, Beyond-Use Dating & Quality Assurance

Nonsterile Compounding and USP <795>

Nonsterile compounding combines federal FD&C Act provisions, Mississippi Article XXXI, and the current USP <795> standard adopted or enforced through applicable law. The revised chapter became official November 1, 2023 and replaced several familiar legacy concepts.

Compounding versus manufacturing

Traditional § 503A compounding is based on receipt of a valid patient-specific prescription or, in limited anticipation, a history of routine valid prescriptions within the established practitioner-patient-pharmacist relationship. It is not large-scale production for resale or office inventory beyond what law permits. A § 503B outsourcing facility is FDA-registered, follows current good manufacturing practice and the statutory conditions, and may compound without patient-specific prescriptions under that federal category.

Mississippi permits compounding within pharmacy practice but requires appropriate facilities, equipment, ingredients, controls, labels, records, and professional oversight. A pharmacy cannot evade manufacturer or wholesaler regulation by calling an identical mass-produced batch “compounded.”

Current USP <795> categories and BUDs

The revised chapter does not use “simple,” “moderate,” and “complex” compounding categories. Those terms belong to the former framework and should not drive current BUD selection.

In the absence of a validated stability study supporting another BUD, the current default maximums include:

• aqueous nonpreserved dosage form: 14 days in a refrigerator;
• aqueous preserved dosage form: 35 days at controlled room temperature or refrigerated;
• nonaqueous oral liquid: 90 days; and
• other nonaqueous dosage forms: 180 days.

The assigned BUD cannot exceed the earliest applicable component expiration or conflict with known chemical, physical, microbiological, or packaging stability. A shorter BUD is required when formulation, container, storage, or ingredient information does not support the maximum. BUD is the date after which the compounded preparation must not be used; it is not the manufacturer expiration assigned under commercial stability studies.

Water activity and presence or effectiveness of a preservative affect category. Simply labeling a liquid “syrup” does not prove it is preserved. Verify the formulation and, when required, preservation effectiveness.

Ingredients, facility, and process

Use USP/NF or appropriate-quality ingredients from approved sources, verify certificates and lot/expiration, and do not use a component withdrawn or prohibited for safety. The designated compounding area is orderly and clean, prevents cross-contamination, and has appropriate balances, measuring devices, ventilation, and containment. Hazardous drugs trigger USP <800> controls in addition to <795>.

Personnel complete initial and ongoing training and demonstrate competence in calculations, measuring, mixing, cleaning, garbing as applicable, and documentation. The pharmacist performs final verification of identity, calculations, appearance, packaging, label, BUD, and storage.

Records

A master formulation record contains the official name/strength/dosage form, components and quantities, calculations, equipment, instructions, packaging, BUD and storage, quality-control steps, and references. A compounding record documents the actual preparation: prescription or batch identifier, preparation date, exact ingredients and lot numbers, measured quantities, personnel, yield, assigned BUD, results, and deviations.

The label identifies the patient when patient-specific, preparation, strength or concentration, directions, quantity, BUD, storage, and pharmacy information required by law. Records must connect the finished preparation to components and personnel for recall.

Exam method

Classify the legal pathway first, then the current BUD category. Check component expiration, water and preservation, container, storage, records, and final verification. Reject answers that use the retired complexity categories or automatically assign the maximum without stability support.

BUD assignment examples

A water-based oral suspension made without an effective preservative receives no more than 14 days refrigerated absent better stability support. A preserved aqueous topical may qualify for up to 35 days at room or refrigerated conditions only if the formulation and preservation support that category. An oil-based oral liquid may receive up to 90 days; a nonaqueous capsule may receive up to 180. If an ingredient expires sooner or published stability supports only 30 days, use the shorter date.

For a refill of a compounded preparation, do not copy the prior label’s BUD automatically. Verify current lot expirations, formulation, package, preparation date, and storage. The new compounding record links every actual component and person to the dispensed preparation so a supplier recall can identify affected patients.

Cleaning records identify area, equipment, agent, concentration, date, and responsible person. A visible residue, scale failure, ingredient mix-up, or unexplained yield triggers investigation and possible quarantine rather than release based only on final appearance.

When a preparation’s appearance, odor, viscosity, pH, weight, or yield falls outside expected limits, quarantine it and investigate the calculation, component identity, equipment, and process. Reworking or relabeling requires documented scientific justification and pharmacist approval.